M

Merck

Makes medicines, vaccines and animal treatments

Principal Scientist - Multiple Teams

Full-TimeUpdated Deadline 11/14/26
$173.2k - $272.6k+ Annual bonus + Long-term incentive
Expert
Bachelor's, Master's, PhD
West Point, PA, USA
In PersonTravel requirements: 10%. Domestic relocation is required.
Biology & BiotechBioprocess & Biomanufacturing
H1B Sponsorship Available

About the job

Requirements
  • A B.S. in Chemical Engineering, Biochemical Engineering, Bioengineering, Pharmaceuticals, Biochemistry, Microbiology, or a related field with 12 years of relevant experience; alternatively, a Master's degree in one of these fields with 10 years of relevant experience, or a Ph.D. in one of these fields with 8 years of relevant experience.
  • Experience with drug product process development, optimization, and/or process characterization of biologics, including monoclonal antibodies, antibody-drug conjugates, and/or fusion proteins.
  • Experience with at-scale biologics drug product manufacturing and fill-finish operations.
  • Experience with late-stage commercialization of biologics programs.
  • Technical expertise in sterile drug product fill-finish manufacturing processes for large molecules, including laboratory and/or fundamental models for key unit operations.
  • Experience with technology transfer and process scale-up to pilot and/or manufacturing scales.
  • Ability to effectively articulate understanding of process science to drive decision-making, impact assessments, and study design in a multidisciplinary team environment.
Responsibilities
  • Execute and provide oversight for biologics product and process design, development, characterization, technology transfer, and commercial validation.
  • Lead and/or serve on cross-functional biologics drug product working groups and manage drug product activities through filing and Process Performance Qualification, including registration stability study execution, process characterization planning and execution, technology transfer control strategy, process development, PPQ readiness, Pre-Approval Inspection readiness, approval, launch, and post-launch support.
  • Ensure commercialization programs meet requirements for science, quality, reliability, schedule, and cost.
  • Drive strategic technical and/or business-process initiatives within the department and partner groups to enable more efficient commercialization of innovative products.
  • Provide mentorship, technical oversight, and strategic guidance to employees, using advanced scientific and technical experience to guide others in addressing non-routine or difficult issues.
  • Develop process and product development plans and influence decisions related to primary packaging and combination-product design.
  • Design and execute drug product development and commercialization studies, new product introduction, and process validation at commercial sites.
  • Ensure fit-for-purpose scale-down models are developed and used; establish and validate platform engineering and scientific models for sterile product and process commercialization.
  • Drive best practices for commercial-site technology transfer, facility fit, and drug product control-strategy development, including classification of process parameters, performance parameters, operating ranges, and in-process controls; influence process demonstration and qualification and shelf-life strategies.
  • Influence chemistry, manufacturing, and controls regulatory strategy; own drug product CMC filing sections; review regulatory strategy and filing readiness; support agency-meeting preparation; and author and review regulatory submissions.
  • Drive continuous, phase-appropriate process optimization toward standardized platforms for liquid, lyophilized, and combination-product presentations.
  • Establish and foster a culture of high performance, innovation, learning, and empowerment.
Desired Qualifications
  • Operations experience in manufacturing potent and sterile drug products at pilot and/or commercial scale.
  • Experience commercializing biologics programs through PPQ and launch.
  • Working knowledge of analytical methods and product attributes for biologics.
  • Working knowledge of regulatory requirements for commercialization and registration of sterile drug products, including application of Quality by Design principles.
  • Working knowledge of current Good Manufacturing Practices for sterile dosage-form manufacturing and current ICH Quality guidelines as applied in Manufacturing Science and Technology or Technical Operations.
  • Working knowledge of statistical methods for design of experiments design and data analysis, statistical process control, multivariate analysis, and/or process analytical technology techniques for manufacturing processes.
  • Experience in data analytics, computer modeling, and digital applications.
  • Working understanding of analytical methods to characterize biologics and other sterile drug products.

About the company

Merck develops prescription medicines, vaccines and veterinary treatments for patients, health systems and animal owners worldwide. Its vaccine portfolio includes Gardasil 9, which helps prevent cancers and other diseases caused by several types of human papillomavirus. The company takes potential treatments through laboratory research and clinical trials, then manufactures and sells approved products to drug distributors, hospitals, physicians and governments. Its animal health division sells medicines and vaccines to veterinarians, farmers and pet owners, while selected drug partnerships also earn shared profits or royalties. Founded in 1891, Merck is headquartered in Rahway, New Jersey.

Company Size

10,001+

Company Stage

IPO

Headquarters

Rahway, New Jersey

Founded

1891

Get referred to Merck

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • U.S. employees build retirement benefits: Merck pairs a defined benefit pension with a matching 401(k).
  • Scientists work within a large research network: Merck reports approximately 24,700 employees in R&D.
  • Animal health adds growth: August 2026 results report Q2 sales of $1.8 billion, up 8% year over year.

What critics are saying

  • Job security faces cuts: Merck's active restructuring program eliminates roles and shrinks its global real estate footprint.
  • Keytruda protection narrows: its main U.S. patent expires in 2028, with additional patents expiring in 2029.
  • Revenue is concentrated: August 2026 results show Keytruda products generated $8.4 billion of Merck's $16.6 billion Q2 sales.

What makes Merck unique

  • Merck extends into farm technology: SenseHub continuously monitors livestock for behavioral and physiological changes.
  • Merck publishes open medical knowledge: its Manuals give clinicians and patients free online references.
  • Merck's donation commitment is open-ended: Mectizan supplies for river blindness continue for as long as needed.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

-19%

1 year growth

-20%

2 year growth

-20%
Yahoo Finance
Oct 31st, 2026
Merck shares climb 2% as analysts raise price targets after $18B third-quarter sales beat

Merck shares rose more than 2% on Friday, a day after the pharmaceutical company posted strong third-quarter results. The S&P 500 fell 1.8% over the same session. Total sales grew 5% to over $18 billion, driven by its cancer drug Keytruda. Adjusted net income fell 4% to nearly $6.2 billion. Both figures beat average analyst estimates, as did its guidance for 2026. Several analysts raised their price targets. Jason Gerberry of Bank of America Securities lifted his to $165 from $163, while Chris Schott of J.P. Morgan raised his to $175 from $165. Both kept buy-equivalent ratings. Merck's dividend currently yields 2.3%.

Yahoo Finance
Oct 30th, 2026
ESMO market reaction: Moderna and Tango shares fall despite positive data, Xencor soars

Investors reacted sharply to cancer data at the European Society for Medical Oncology (ESMO) meeting, and good results did not always lift shares. Moderna's shares fell by double digits after it and Merck & Co. presented details on their personalised cancer vaccine, intismeran autogene. Investors want more data on other tumour types and on the commercial outlook for a vaccine made through a complex, personalised process. Tango Therapeutics fell about 20% despite an 82% response rate for its pancreatic cancer drug combination. It also announced plans to lay off 14% of its workforce, and analysts cited rising competition. Xencor was a top winner. Its kidney cancer antibody, XmAb819, showed a 46% response rate at the highest dose tested.

Yahoo Finance
Oct 29th, 2026
Merck raises outlook on lower tax rate as Q3 sales rise 5% to $18.1B

Merck raised its full-year earnings outlook, helped by a lower tax rate, and its shares rose about 5% in Thursday morning trading. Third-quarter sales rose 5% to about $18.1 billion, though about $550 million of that came from the timing of customer purchases. Adjusted earnings per share fell 3% to $2.49. Spending on launches and research outpaced sales, and interest expense climbed. Merck now expects a non-GAAP tax rate of 32% to 33%, down from 35% to 36%. Keytruda Qlex, a shot injected under the skin, brought in $830 million, up from $463 million last quarter. Winrevair sales rose 93% to $694 million. Generic competition hit older drugs; Bridion sales fell 67%. Keytruda's main US patent expires in 2028.

Yahoo Finance
Oct 29th, 2026
Merck beats Q3 estimates with $18.1B revenue and raises 2026 profit outlook

Merck beat third-quarter 2026 expectations and raised its full-year profit outlook. Shares rose more than 2% in premarket trading on Thursday. Earnings per share were $2.49, against a consensus estimate of $2.09. Revenue reached $18.1 billion, up 4% excluding foreign exchange effects, ahead of the $17.28 billion analysts expected. Cancer drug Keytruda sold $8.6 billion, up 6%, including $830 million from its subcutaneous version, Keytruda Qlex. Winrevair, a treatment for pulmonary arterial hypertension, brought in $694 million, up 93%. Gardasil vaccine sales rose 14% to about $2 billion, and Animal Health revenue grew 4% to $1.7 billion. Merck now expects 2026 earnings per share of $2.77 to $2.82, up from $2.66 to $2.76. It narrowed its revenue guidance to between $66.8 billion and $67.3 billion.

Yahoo Finance
Oct 28th, 2026
Merck earnings preview: flat Q3 revenue expected after $16.61B last quarter

Merck (NYSE:MRK) reports third-quarter earnings on Thursday before market open. It is the first of its peers to report this season. Analysts expect revenue to be flat year on year, slowing from a 3.7% rise in the same quarter last year. Estimates have largely held steady over the past 30 days. Last quarter, Merck beat revenue expectations with $16.61 billion, up 5.1% year on year. It also beat analysts' earnings per share estimates but missed full-year EPS guidance estimates. Pharmaceutical shares have risen 3.6% on average over the last month. Merck is down 4.5% over the same period.